Am­gen, look­ing for a path in­to red-hot 'mol­e­c­u­lar glues,' inks a deal with Plex­i­um for 2 pro­grams, po­ten­tial­ly more

As phar­ma con­tin­ues to seek new break­throughs across drug modal­i­ties, few ar­eas have gar­nered more in­ter­est than pro­tein degra­da­tion. And Am­gen is tak­ing a fly­er out on a small biotech that thinks its broad ap­proach to de­grad­er R&D could spell a fruit­ful re­la­tion­ship with the drug gi­ant.

Am­gen could pay more than $500 mil­lion in down­stream mile­stones with an undis­closed amount up­front for ac­cess to two pro­grams — and po­ten­tial­ly more — from Plex­i­um, a biotech work­ing on an “ag­nos­tic” ap­proach to tar­get­ed pro­tein degra­da­tion, the com­pa­nies said Thurs­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER